Nuclear matrix protein 22 chemiluminescent immunodetection reagent kit and preparing method thereof

Abstract

The invention relates to the field of immunoassay medicine, in particular to a nuclear matrix protein 22 chemiluminescent immunodetection reagent kit and a preparing method thereof. The reagent kit can be used in clinic for the early diagnosis and the post-operation therapeutic effect monitoring of bladder cancer. The reagent kit provided by the invention comprises an NMP22 calibrator, a solid-phase carrier pre-coated by an NMP22 monoclonal antibody, an enzyme marker of the NMP22 monoclonal antibody, a chemiluminescent substrate solution acting with the enzyme and a concentrated washing solution. The reagent kit has the advantage that bladder cancer can be simply, conveniently and noninvasively diagnosed in an early phase.

Description

technical field [0001] The invention relates to the field of immunoanalysis medicine. Specifically, the invention provides a nuclear matrix protein 22 (NMP22) chemiluminescence immunoassay detection kit and a preparation method thereof. Background technique [0002] Bladder tumors are the most common tumors in the urinary system, and more than 90% are transitional cell carcinomas, of which more than 80% are non-invasive superficial carcinomas, and 10%-20% develop into invasive bladder carcinomas. Transitional cell carcinoma of the bladder is the most common malignant tumor of the urinary system, mostly occurring between the ages of 50 and 70. This disease has a high mortality rate, and early detection and diagnosis play an important role in treatment and prognosis. Data show that the 5-year survival rate of patients diagnosed in the early stage of the disease is greater than 90%, while the 5-year survival rate of patients diagnosed in the late stage is only about 15%-30%. ...

AI Technical Summary

Problems solved by technology

At present, the diagnosis and postoperative review of bladder cancer mainly rely on cystoscopy and urine cytology examination. Although the former is accurate, it is an invasive examination, which is complicated, time-consuming, laborious, expensive, and brings great pain to the patient. Many patients are resistant to this method, and it is difficult to find carcinoma in situ or flat carcinoma; urine cytology is non-invasive and has good specificity, but low sensitivity. It is sensitive to tumors with lower stages and better differentiation. Only 30% or lower, and it is greatly affected by the subjective factors of the diagnostician

The limitations of cystoscopy and urine cytology limit the application of bladder cancer diagnosis, so it is of great significance to find a simple, non-invasive and early diagnosis of bladder cancer detection method and equipment

Images